sign in sign up
<<
Home , CXCR4 antagonist, Momelotinib

PROTOCOL ALERT

New Clinical Trials Recently Added to the National Cancer Institute’s Database

Bladder Cancer Phase 1/1b Study to Evaluate the Safety Trial IDs: 556-15, NCI-2015-01502, and Tolerability of CPI-444 Alone and NCT02553447 Type: Biomarker/Laboratory analysis, A Study Of In Patients in Combination With in Treatment With Locally Advanced Or Metastatic Advanced Cancers in Treating Minimal Residual Age: 18 to 75 Urothelial Cancer (JAVELIN Bladder Status: Active Disease in Patients With Chronic Trial IDs: UW14113, NCI-2015-02269, 100) Phase: Phase I Lymphocytic After Front- 2015-0996, NCT02652468 Status: Active Type: Treatment Line Therapy Phase: Phase III Age: 18 and over Status: Active Esophageal Cancer Type: Treatment Trial IDs: CPI-444-001, NCI-2016- Phase: Phase II Age: 18 and over 00227, NCT02655822 Type: Biomarker/Laboratory analysis, Proton Beam Radiation Therapy Trial IDs: B9991001, NCI-2016-00304, Treatment or Intensity-Modulated Radiation 2015-003262-86, JAVELIN Bladder 100, Circulating Tumor Cells in Operative Age: 18 and over Therapy in Treating Patients With NCT02603432 Blood in Patients With Bladder Cancer Trial IDs: MC1481, NCI-2015-02153, Esophageal Cancer Status: Not yet active NCT02649387 Status: Active A Study of Intravesical Apaziquone Phase: No phase specified Phase: Phase III as a Surgical Adjuvant in Patient Type: Biomarker/Laboratory analysis, Ibrutinib or Idelalisib in Treating Type: Treatment Undergoing TURBT Natural history/Epidemiology Patients With Persistent or Relapsed Age: 18 and over Status: Active Age: 18 and over Chronic Lymphocytic Leukemia, Small Trial IDs: 2011-1036, NCI-2012-00078, Phase: Phase III Trial IDs: 4B-15-7, NCI-2015-01063, Lymphocytic , or Non- NCT01512589 Type: Treatment NCT02514408 Hodgkin Lymphoma After Donor Stem Age: 18 and over Cell Transplant Glutamine in Reducing the Severity of Trial IDs: SPI-EOQ-13-305, NCI-2016- Status: Not yet active Mucositis or Esophagitis in Patients Chronic Lymphocytic 00340, NCT02563561 Phase: Phase II With Advanced Cancer Receiving Leukemia Type: Treatment mTOR Inhibitor-Based A Study to Evaluate the Efficacy Ublituximab + TGR-1202 Compared Age: 18 and over or Radiation Therapy and Safety of Rivaroxaban Venous to + Chlorambucil in Trial IDs: 2561.00, NCI-2015-02201, Status: Active Thromboembolism (VTE) Prophylaxis Patients With Chronic Lymphocytic NCT02662296 Phase: Phase III in Ambulatory Cancer Participants Leukemia Type: Supportive care Status: Active Status: Active Study of EDO-S101, A First-in-Class Age: Not specified Phase: Phase III Phase: Phase III Alkylating HDACi Fusion Molecule, Trial IDs: 2013-0308, NCI-2014-00917, Type: Prevention Type: Treatment in Relapsed/Refractory Hematologic NCT01952847 Age: 18 and over Age: 18 and over Malignancies Trial IDs: CR107047, NCI-2016-00410, Trial IDs: UTX-TGR-304, NCI-2016- Status: Not yet active Early Palliative Care With Standard 2015-001630-21, 39039039STM4001, 00375, NCT02612311 Phase: Phase I Care or Standard Care Alone in NCT02555878 Type: Biomarker/Laboratory analysis, Improving Quality of Life of Patients Abatacept, Cyclosprine, Tacrolimus, Treatment With Incurable Lung or Non-colorectal Study of (MK-3475) and Methotrexate in Preventing Graft- Age: 18 and over Gastrointestinal Cancer and Their in Participants With High Risk Non- versus-Host Disease in Patients with Trial IDs: EDO-S101-1001, NCI-2016- Family Caregivers muscle Invasive Bladder Cancer High-Risk Leukemia Undergoing Stem 00310, NCT02576496 Status: Active (MK-3475-057/KEYNOTE-057) Cell Transplant Phase: Phase III Status: Active Status: Active Laboratory-Treated T Cells in Treating Type: Supportive care Phase: Phase II Phase: Phase II Patients with B-cell Lymphoma, Age: 18 and over Type: Treatment Type: Supportive care Chronic Lymphocytic Leukemia, or Trial IDs: A221303, NCI-2014-01943, Age: 18 and over Age: 6 and over Acute Lymphocytic Leukemia NCT02349412 Trial IDs: 3475-057, NCI-2016-00312, Trial IDs: 2692.00, NCI-2016-00220, Status: Active 2014-004026-17, NCT02625961 PBMTC PROTOCOL GVH 1201, Phase: Phase I A Study of BBI608 Administered NCT01743131 Type: Biomarker/Laboratory analysis, With Paclitaxel in Adult Patients With Emtansine in Treating Treatment Advanced Malignancies Patients with HER2 Amplified or CXCR4 Antagonist BL-8040 in Age: 18 to 73 Status: Active Mutant Advanced Cancers Mobilizing Stem Cells for Donor Trial IDs: 16-C-0054, NCI-2016-00101, Phase: Phase II, Phase I Status: Active Transplant in Healthy Donors and P152152, NCT02659943 Type: Treatment Phase: Phase II Patients With Advanced Hematological Age: 18 and over Type: Biomarker/Laboratory analysis, Malignancies Genetically Modified T-Cell Trial IDs: BBI608-201, NCI-2014-01566, Treatment Status: Not yet active Therapy in Treating Patients NCT01325441 Age: 18 and over Phase: Phase II With Advanced ROR1+ Trial IDs: 15-335, NCI-2016-00262, Type: Biomarker/Laboratory analysis, Malignancies A Phase Ib Study of MEK162 Plus NCT02675829 Treatment Status: Not yet active BYL719 in Adult Patients With Selected Age: 18 to 75 Phase: Phase I Advanced Solid Tumors Paclitaxel Albumin-Stabilized Trial IDs: 201602037, NCI-2016-00197, Type: Biomarker/Laboratory analysis, Status: Active Nanoparticle Formulation after NCT02639559 Treatment Phase: Phase II, Phase I Cisplatin-Based Chemotherapy and Age: 18 and over Type: Treatment Surgery in Treating Patients With Cholecalciferol in Treating Patients Trial IDs: 9330, NCI-2015-01753, Age: 18 and over High-Risk Bladder Cancer with Newly Diagnosed Non-Hodgkin 9330A, NCT02706392 Trial IDs: CMEK162X2109, NCI-2012- Status: Not yet active Lymphoma or Chronic Lymphocytic 00874, 2011-002578-21, NCT01449058 Phase: Phase II Leukemia with Vitamin D Deficiency Donor TCR Alpha-Beta and CD19- Type: Biomarker/Laboratory analysis, Status: Active Depleted Stem Cell Transplant in Probiotic LGG for Prevention of Treatment Phase: Phase II Treating Patients With Relapsed or Side Effects in Patients Undergoing Age: 18 and over Type: Biomarker/Laboratory analysis, Refractory Chemoradiation for Gastrointestinal Trial IDs: MC1551, NCI-2016-00133, Treatment Status: Active Cancer NCT02718742 Age: 19 and over Phase: No phase specified Status: Active

32 Oncology Times April 25, 2016 Phase: Phase III Trial IDs: ADN011, NCI-2016-00165, Status: Active PROTOCOL ALERT Type: Biomarker/Laboratory analysis, 2015-001360-19, NCT02411084 Phase: Phase III continued from page 32 Supportive care, Treatment Type: Treatment Age: not specified Safety Follow-up of Treatment With Age: 18 to 70 Trial IDs: 2448.00, NCI-2010-02035, Remestemcel-L in Pediatric Patients Trial IDs: BMTCTN1101, NCI-2014- Phase: Phase II, Phase I NCT01231412 Who Have Failed to Respond to Steroid 00307, 2U10HL069294-11, 715, Type: Supportive care, Treatment Treatment for Acute GVHD NCT01597778 Age: 18 and over P3 Study of Umbilical Cord Blood Status: Active Trial IDs: 201404101, NCI-2013-00650, Cells Expanded With MPCs for Phase: Phase III Phase 3 Frontline Therapy Trial in NCT01790035 Transplantation in Patients With Type: Natural history/Epidemiology, Patients With Advanced Classical Hematologic Malignancies Treatment Hodgkin Lymphoma Study of Carfilzomib With Irinotecan Status: Active Age: 2 months to 17 years Status: Enrolling by invitation in Irinotecan-Sensitive Malignancies Phase: Phase III Trial IDs: MSB-GVHD002, NCI-2016- Phase: Phase III and Small Cell Lung Cancer Patients Type: Treatment 00303, NCT02652130 Type: Treatment Status: Active Age: 65 and under Age: 18 and over Phase: Phase II, Phase I Trial IDs: CB-AB006, NCI- Donor Peripheral Blood Stem Trial IDs: C25003, NCI-2012-03101, Type: Biomarker/Laboratory analysis, 2013-00758, 2012-0166, Cell transplantation Followed by 12/LO/1950, 2011-005450-60, Treatment NCT01854567 Lenalidomide and Sirolimus in JapicCTI-142491, U1111-1161-4937, Age: 18 and over Treating Patients With High-Risk NCT01712490 Trial IDs: CRAB CTC 11-001, NCI- in Treating Younger Multiple Myeloma 2014-02260, CAR-IST-553, NCI-2013- Patients With Relapsed B-cell Acute Status: Active P3 Study of Umbilical Cord Blood 02243, NCT01941316 Lymphoblastic Leukemia Phase: Phase II, Phase I Cells Expanded With MPCs for Status: Active Type: Supportive care, Treatment Transplantation in Patients With HuMax®-TF-ADC Safety Study in Phase: Phase III Age: 18 to 70 Hematologic Malignancies Patients With Solid Tumors Type: Biomarker/Laboratory analysis, Trial IDs: IUCRO-0307, NCI- Status: Active Status: Active Treatment 2011-00266, 1012-24, 1105005328, Phase: Phase III Phase: Phase II, Phase I Age: 1 to 30 NCT01303965 Type: Treatment Type: Biomarker/Laboratory analysis, Trial IDs: AALL1331, NCI-2014-00631, Age: 65 and under Treatment COG-AALL1331, NCT02101853 Donor -Induced Killer Trial IDs: CB-AB006, NCI-2013-00758, Age: 18 and over Cells in Treating Patients With 2012-0166, NCT01854567 Trial IDs: GEN701, NCI-2014-01166, Calcineurin Inhibitor-Free Myelodysplasia or Myeloproliferative NCT02001623 Interventions for Prevention of Graft- Disorders Previously Treated With A Study to Evaluate a Therapeutic Versus-Host Disease (BMT CTN 1301) Donor Stem Cell Transplant Vaccine, ASP0113, in Cytomegalovirus Vaccine Therapy and Iscomatrix With Status: Active Status: Active (CMV)-Seropositive Recipients or Without Cyclophosphamide and Phase: Phase III Phase: Phase II, Phase I Undergoing Allogeneic, Hematopoietic Celecoxib in Treating Patients With Type: Treatment Type: Treatment Cell Transplant (HCT) Thoracic Malignancies or Tumors That Age: 1 to 65 Age: 50 and over Status: Active Have Spread to the Chest Cavity Trial IDs: BMTCTN1301, NCI-2015- Trial IDs: BMT217, NCI-2011- Phase: Phase III Status: Temporarily closed 01813, U01HL069294, NCT02345850 01493, 5136, SU-04202010-5724, Type: Prevention Phase: Phase II, Phase I NCT01392989 Age: 18 and over Type: Treatment A Prospective Study of Remestemcel-L, Trial IDs: 0113-CL-1004, NCI-2013- Age: 18 and over Ex-vivo Cultured Adult Human 01949, 2013-000903-18, NCT01877655 Hodgkin Lymphoma, Trial IDs: 14-C-0053, NCI-2014- Mesenchymal Stromal Cells, for the Adult 02465, 140053, 348360, P131392, Treatment of Pediatric Patients Who A Study to Evaluate the Efficacy NCT02054104 Have Failed to Respond to Steroid Autologous Peripheral Blood Stem Cell and Safety of Rivaroxaban Venous Treatment for Acute GVHD Transplant in Treating Patients With Thromboembolism (VTE) Prophylaxis Pembrolizumab, Combination Status: Active Lymphoma in Ambulatory Cancer Participants Chemotherapy, and Celecoxib Phase: Phase III Status: Active Status: Active in Treating Patients With Type: Treatment Phase: Phase III, Phase II Phase: Phase III Advanced Colorectal, Appendix, Age: 2 months to 17 years Type: Treatment Type: Prevention Gastroesophageal, Pancreatic, or Trial IDs: MSB-GVHD001, NCI-2015- Age: Under 70 Age: 18 and over Biliary Tract Cancer That Cannot Be 00354, NCT02336230 Trial IDs: MT 2004-24, NCI-2010- Trial IDs: CR107047, NCI-2016-00410, Removed by Surgery 01414, 0508M72589, 2005LS048, 2015-001630-21, 39039039STM4001, Status: Active UVADEX® and ECP for the Treatment UMN-2005LS048, UMN-0508M72589, NCT02555878 Phase: Phase II, Phase I of Pediatric Patients With Steroid UMN-MT2004-24, NCT00345865 Type: Biomarker/Laboratory analysis, Refractory Acute Graft Versus Host Before Donor Stem Cell Treatment Disease Graft-Versus-Host Disease Prophylaxis Transplant in Treating Patients With Age: 18 and over Status: Not yet active in Treating Patients With Hematologic Hematologic Diseases Trial IDs: HCI76239, NCI-2015- Phase: Phase III Malignancies Undergoing Unrelated Status: Active 00123, 3475-085, 76239, MK-3475 GI, Type: Treatment Donor Peripheral Blood Stem Cell Phase: Phase II, Phase I NCT02268825 Age: 1 to 21 Transplant Type: Treatment Trial IDs: TKS-2014-001, NCI-2015- Status: Active Age: 70 and under 01646, NCT02524847 Phase: Phase III Trial IDs: HIMSUM, NCI-2012-00639, Graft-Versus-Host Type: Biomarker/Laboratory analysis, NCT00058825 Disease Study of BEGEDINA® vs Supportive care, Treatment Graft-Versus-Host Disease Prophylaxis “Conventional Treatment” for Treating Age: not specified Fludarabine Phosphate, in Treating Patients With Hematologic Steroid-Resistant Acute GvHD Trial IDs: 2448.00, NCI-2010-02035, Cyclophosphamide, Total-Body Malignancies Undergoing Unrelated Status: Not yet active NCT01231412 Irradiation, and Donor Bone Marrow Donor Peripheral Blood Stem Cell Phase: Phase III Transplant Followed by Donor Natural Transplant Type: Treatment Double Cord Versus Haploidentical Killer Cell Therapy, Mycophenolate Status: Active Age: 18 to 65 (BMT CTN 1101) continued on page 34 oncology-times.com Oncology Times 33 Trial IDs: S1400, NCI-2014-00627, Melanoma BRIM8: A Study of PROTOCOL ALERT S1400A, S1400B, S1400C, S1400D, and With or Adjuvant Therapy in Patients With continued from page 33 S1400E, S1400I, NCT02154490 Without in Treating Resected Cutaneous BRAF Mutant Patients With Stage III-IV Melanoma Melanoma Quercetin in Preventing Venous That Cannot Be Removed by Surgery Status: Active Mofetil, and Tacrolimus in Thromboembolic Events in Patients Status: Active Phase: Phase III Treating Patients with Hematologic with , Non-small Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Cancer Cell Lung Cancer, or Colorectal Type: Biomarker/Laboratory analysis, Treatment Status: Active Cancer That is Advanced or Cannot Be Treatment Age: 18 and over Phase: Phase II, Phase I Removed by Surgery Age: 18 and over Trial IDs: GO27826, NCI-2012- Type: Treatment Status: Active Trial IDs: EA6141, NCI-2014-02674, 03085, 2011-004011-24, G027826, Age: Any age Phase: Phase III, Phase II NCT02339571 NCT01667419 Trial IDs: 2230.00, NCI-2010- Type: Supportive care 00106, FHCRC-2230.00, IR-6771, Age: 18 and over Neurotropic Melanoma of the Head Sargramostim or Hypertonic Saline NCT00789776 Trial IDs: 14-114, NCI-2015-01705, and Neck Before Sentinel Lymph Node Biopsy NCT02195232 Status: Active in Treating Patients With Stage IB-II Autologous or Donor Cytotoxic Phase: Phase III Melanoma T-Lymphocytes in Treating Patients Dimaleate With or Without Type: Treatment Status: Active With Epstein-Barr Virus-Positive in Treating Patients Age: 18 and over Phase: Phase III Hematologic Malignancy Wwith Newly Diagnosed Stage IV or Trial IDs: TROG 08.09, NCI- Type: Treatment Status: Active Recurrent, EGFR Mutation Positive 2015-00466, 2009/039, Age: 18 to 75 Phase: Phase II, Phase I Non-small Cell Lung Cancer ACTRN12610000478011, Trial IDs: 10-000062, NCI-2013-00645, Type: Treatment Status: Active NCT00975520 10-001674, 11-002177, NCT01826864 Age: Any age Phase: Phase III, Phase II Trial IDs: ALCI, NCI-2012-00653, Type: Biomarker/Laboratory analysis, Hypofractionated or Single Dose and 9936-ALCI, H-9936, NCT00070226, Treatment Image-Guided Radiation Therapy Followed by Ipilimumab and NCT00671164, NCT00062868 Age: Not specified in Treating Patients With Metastatic Nivolumab or Ipilimumab and Trial IDs: S1403, NCI-2014-02405, BI Cancer Nivolumab Followed by Dabrafenib 1200.124, NCT02438722 Status: Active and Trametinib in Treating Patients Lung Cancer, Non- Phase: Phase III With Stage III-IV BRAFV600 Small Cell Comparison of Different Types of Type: Treatment Melanoma Safety and Efficacy Study of Abraxane Surgery in Treating Patients With Stage Age: 18 and over Status: Temporarily closed in Combination With Carboplatin to IA Non-Small Cell Lung Cancer Trial IDs: 10-154, NCI-2010-02150, Phase: Phase III Treat Advanced NSCL Cancer in the Status: Active NCT01223248 Type: Biomarker/Laboratory analysis, Elderly Phase: Phase III Treatment Status: Active Type: Treatment Ipilimumab or High-Dose Age: 18 and over Phase: Phase IV Age: 18 and over Alfa-2b in Treating Patients With Trial IDs: EA6134, NCI-2014-01747, Type: Treatment Trial IDs: CALGB 140503, NCI-2009- High-Risk Stage III-IV Melanoma That NCT02224781 Age: 70 and over 00447, CDR0000555324, ECOG-40503, Has Been Removed by Surgery Trial IDs: ABI-007-NSCL-005, NCI- NCT00499330 Status: Active PV-10 vs Chemotherapy or Oncolytic 2014-02488, NCT02151149 Phase: Phase III Viral Therapy for Treatment of Locally Safety and Efficacy of Talactoferrin in Type: Biomarker/Laboratory analysis, Advanced Cutaneous Melanoma Afatinib Treatment for Patients With Addition to Standard Chemotherapy Treatment Status: Active EGFR Mutation Positive NSCLC Who in Patients With Non-small Cell Lung Age: 18 and over Phase: Phase III Are Age 70 or Older Cancer Trial IDs: E1609, NCI-2011-02649, Type: Treatment Status: Active Status: Active CDR0000692568, ECOG-E1609, Age: 18 and over Phase: Phase IV Phase: Phase III NCT01274338 Trial IDs: PV-10-MM-31, NCI-2015- Type: Treatment Type: Treatment 00568, NCT02288897 Age: 70 and over Age: 18 and over A Phase 3 Study to Compare Efficacy Trial IDs: 1200.209, NCI-2016-00277, Trial IDs: LF-0208, NCI-2009-01425, and Safety of to Dacarbazine Neuroblastoma NCT02514174 NCT00706862 in the Treatment of Patients With Non-Resectable or Metastatic Stage Combination Chemotherapy and Study in Progressive Anemia Treatment for Advanced 3 or Stage 4 Melanoma Carrying a Fixed or Flexible Administration of or Relapsed Non-Small Cell Lung Non-Small Cell Lung Cancer (NSCLC) Mutation in the Juxta Membrane in Treating Younger Patients Cancer Patients Receiving Chemotherapy Domain of C-Kit With Cancer Status: Active Status: Active Status: Active Status: Active Phase: Phase III, Phase II Phase: Phase III Phase: Phase III Phase: Phase III Type: Treatment Type: Supportive care Type: Treatment Type: Treatment Age: 18 and over Age: 18 and over Age: 18 and over Age: 1 to 25 Trial IDs: NLG0301, NCI-2013-00592, Trial IDs: 20070782, NCI-2010-00172, Trial IDs: AB08026, NCI-2011-03815, Trial IDs: 2013-062, NCI-2013-02001, 1209-1184, NCT01774578 NCT00858364 NCT01280565 NCT01987596

Lung-MAP: Biomarker-Targeted F18PET/CT Versus TC- Study of a Melanoma Response and Biology-Based Risk Second-Line Therapy in Treating MDP Scanning to Detect Vaccine in Stage IIb, IIc, and III Factor-Guided Therapy in Treating Patients With Recurrent Stage IV Bone Mets Melanoma Patients Younger Patients With Non-high Risk Squamous Cell Lung Cancer Status: Active Status: Active Neuroblastoma Status: Active Phase: Phase III Phase: Phase III Status: Active Phase: Phase III, Phase II Type: Diagnostic Type: Treatment Phase: Phase III Type: Biomarker/Laboratory analysis, Age: 18 and over Age: 18 to 75 Type: Biomarker/Laboratory analysis, Treatment Trial IDs: AMI-2008-01, NCI-2014- Trial IDs: 103A-301, NCI-2012-01351, Treatment Age: 18 and over 02587, NCT00882609 NCT01546571 Age: 17 months and under

34 Oncology Times April 25, 2016 Type: Treatment Trial IDs: 14-114, NCI-2015-01705, Gemcitabine and Nab-paclitaxel PROTOCOL ALERT Age: 21 and under NCT02195232 Combined With continued from page 34 Trial IDs: NMTRC010, NCI-2015- in Participants With Previously 01871, NCT02139397 Study of Ibrutinib vs Placebo, in Untreated Metastatic Pancreatic Combination With Nab-paclitaxel Ductal Adenocarcinoma Trial IDs: ANBL1232, NCI-2014-00677, OKT3/Humanized 3F8 Bispecific and Gemcitabine, in the First Line Status: Active NCT02176967 Antibody-Activated T Lymphocytes, Treatment of Patients With Metastatic Phase: Phase III OPT-821 With Vaccine Therapy and Aldesleukin, and Sargramostim in Pancreatic Adenocarcinoma Type: Treatment Beta-Glucan in Treating Younger Treating Younger Patients with GD2- (RESOLVE) Age: 18 and over Patients With High-Risk Neuroblastoma Positive Metastatic, Recurrent or Status: Active Trial IDs: GS-US-370-1296, Status: Active Refractory Solid Tumors Phase: Phase III, Phase II NCI-2014-02652, 2014-004480-20, Phase: Phase II, Phase I Status: Temporarily closed Type: Treatment NCT02101021 Type: Treatment Phase: Phase II, Phase I Age: 18 and over Age: 21 and under Type: Biomarker/Laboratory analysis, Trial IDs: PCYC-1137-CA, Thyroid Cancer Trial IDs: 05-075, NCI-2009-01362, Treatment NCI-2015-01722, NCT02436668 NCT00911560 Age: 13 moths to 29 years Study Comparing Complete Remission Trial IDs: 2013-171, NCI-2014-01149, Thoracic Epidural or Intravenous After Treatment With / Vaccine Therapy and/or Glycosylated 1403012875, NCT02173093 Patient Controlled Pain Management Placebo in Patient With Differentiated Recombinant Human Interleukin-7 in Treating Patients Undergoing Liver Thyroid Cancer After Standard Therapy in Treating Nivolumab With or Without or Pancreatic Surgery Status: Active Younger Patients With High Risk Solid Ipilimumab in Treating Younger Status: Active Phase: Phase III Tumors Patients With Recurrent or Refractory Phase: Phase III Type: Biomarker/Laboratory analysis, Status: Active Solid Tumors or Sarcomas Type: Supportive care Treatment Phase: Phase II, Phase I Status: Active Age: 18 and over Age: 18 and over Type: Treatment Phase: Phase II, Phase I Trial IDs: 2011-0146, NCI-2011-03284, Trial IDs: D1532C00065, NCI-2013- Age: 19 months to 35 years Type: Biomarker/Laboratory analysis, NCT01438476 01983, EudraCT 2013-000423-14, Trial IDs: 07-C-0206, NCI-2013-01440, Treatment NCT01843062 070206, 339168, NCT00526240, P6941, Age: 12 months to 30 years Surgery With or Without NCT00923351 Trial IDs: ADVL1412, NCI-2014-01222, Intraperitoneal Drainage in Improving A Study of BBI608 Administered NCT02304458 Complication Rate in Patients With With Paclitaxel in Adult Patients With Vorinostat and Etoposide in Treating Pancreatic Disease Advanced Malignancies Younger Patients With Refractory or Status: Active Status: Active Pancreatic Cancer Relapsed Solid Tumors Phase: Phase III Phase: Phase II, Phase I Status: Active Preoperative Biliary Drainage in Type: Health services research, Type: Treatment Phase: Phase II, Phase I Resectable Pancreatic or Periampullary Treatment Age: 18 and over Type: Biomarker/Laboratory analysis, Cancer Age: 18 and over Trial IDs: BBI608-201, NCI-2014-01566, Treatment Status: Active Trial IDs: H-28324, NCI-2012-01881, NCT01325441 Age: 4 to 21 Phase: Phase IV NCT01441492 Trial IDs: 10-096, NCI-2011-00493, Type: Treatment The Efficacy of CASAD in Patients NCT01294670 Age: 18 and over Combination Chemotherapy With or With Diarrhea Related to Medullary Trial IDs: CDM00047339, Without Stereotactic Body Radiation Thyroid Cancer To Find a Safe Dose and Show Early NCI-2016-00348, E7059, Therapy in Treating Patients with Status: Active Clinical Activity of Weekly Nab- NCT01774019 Locally Advanced Pancreatic Cancer Phase: Phase II, Phase I paclitaxel in Pediatric Patients With Status: Active Type: Supportive care Recurrent/ Refractory Solid Tumors Gemcitabine Hydrochloride With Phase: Phase III Age: Not specified Status: Active or Without Hydrochloride Type: Biomarker/Laboratory analysis, Trial IDs: SAL 2012-0584, Phase: Phase II, Phase I Followed By the Same Chemotherapy Treatment NCI-2014-00167, NCT01739634 Type: Biomarker/Laboratory analysis, Regimen With or Without Radiation Age: Over 18 Treatment Therapy and or Trial IDs: PANC0015, NCI-2013-01658, Sapanisertib in Treating Patients Age: 6 months to 21 years Fluorouracil in Treating Patients With 5136, NCT01926197 With Newly Diagnosed or Refractory/ Trial IDs: ABI-007-PST-001, NCI-2015- Pancreatic Cancer That Has Been Metastatic Anaplastic Thyroid Cancer 00737, NCT01962103 Removed By Surgery Glufosfamide Versus 5-FU in Second Status: Active Status: Active Line Metastatic Pancreatic Cancer Phase: Phase II, Phase I Phase: Phase III, Phase II Status: Active Type: Biomarker/Laboratory analysis, WEE1 Inhibitor MK-1775 and Type: Biomarker/Laboratory analysis, Phase: Phase III Treatment Irinotecan Hydrochloride in Treating Treatment Type: Treatment Age: 18 and over Younger Patients With Relapsed or Age: 18 and over Age: 18 and over Trial IDs: 14-223, NCI-2015-01607, Refractory Solid Tumors Trial IDs: RTOG 0848, Trial IDs: EP-GF-301, NCI-2013-02181, NCT02244463 Status: Active NCI-2011-01987, CDR0000659092, NCT01954992 Phase: Phase II, Phase I NCT01013649 Genetically Modified Lymphocytes in Type: Biomarker/Laboratory analysis, Nab-Paclitaxel and Gemcitabine Treating Patients With Thyroglobulin- Treatment Quercetin in Preventing Venous vs Gemcitabine Alone as Adjuvant Expressing Thyroid Cancer That Is Age: 1 to 21 Thromboembolic Events in Patients Therapy for Patients With Resected Recurrent or Metastatic and Cannot Be Trial IDs: ADVL1312, NCI-2014-00547, With Pancreatic Cancer, Non-small Pancreatic Cancer (the “Apact” Study) Removed by Surgery NCT02095132 Cell Lung Cancer, or Colorectal Status: Active Status: Active Cancer That is Advanced or Cannot Be Phase: Phase III Phase: Phase II, Phase I Study of DFMO in Combination With Removed by Surgery Type: Treatment Type: Treatment Bortezomib for Relapsed or Refractory Status: Active Age: 18 and over Age: 18 to 66 Neuroblastoma Phase: Phase III, Phase II Trial IDs: ABI-007-PANC-003, Trial IDs: 15-C-0090, NCI-2015-00499, Status: Active Type: Supportive care NCI-2014-00810, 2013-003398-91, 1412-1366, 150090, 342570, 8340274, Phase: Phase II, Phase I Age: 18 and over NCT01964430 P141702, RD14-XII-05, NCT02390739 oncology-times.com Oncology Times 35